ArticleCureus2025
Avacopan as a Steroid-Sparing Therapy in Relapsing Granulomatosis With Polyangiitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease that causes inflammation in small and medium-sized blood vessels, affecting organs such as the lungs, kidneys, and sinuses. We report the case of a 66-year-old man with relapsing GPA. He first presented with sinus and ear symptoms, which were managed with steroids and other immunosuppressive drugs. After many years of remission, he relapsed with nasal congestion, nosebleeds, and lung nodules. During his latest flare, he was treated with high-dose prednisone, rituximab, and avacopan, a new oral drug that blocks the C5a receptor. Avacopan helped reduce inflammation and allowed for a significant decrease in steroid use. The patient's rapid improvement supports the role of avacopan as a steroid-sparing agent in GPA management, offering a promising way to reduce the harmful side effects of long-term steroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.